JP2022534261A5 - - Google Patents

Info

Publication number
JP2022534261A5
JP2022534261A5 JP2021570368A JP2021570368A JP2022534261A5 JP 2022534261 A5 JP2022534261 A5 JP 2022534261A5 JP 2021570368 A JP2021570368 A JP 2021570368A JP 2021570368 A JP2021570368 A JP 2021570368A JP 2022534261 A5 JP2022534261 A5 JP 2022534261A5
Authority
JP
Japan
Prior art keywords
compound according
alkyl
pharmaceutically acceptable
ring
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021570368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534261A (ja
JP7696834B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/092351 external-priority patent/WO2020238900A1/en
Publication of JP2022534261A publication Critical patent/JP2022534261A/ja
Publication of JP2022534261A5 publication Critical patent/JP2022534261A5/ja
Application granted granted Critical
Publication of JP7696834B2 publication Critical patent/JP7696834B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021570368A 2019-05-27 2020-05-26 Dna依存性タンパク質キナーゼ阻害剤 Active JP7696834B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/088573 2019-05-27
CN2019088573 2019-05-27
PCT/CN2020/092351 WO2020238900A1 (en) 2019-05-27 2020-05-26 Dna-dependent protein kinase inhibitor

Publications (3)

Publication Number Publication Date
JP2022534261A JP2022534261A (ja) 2022-07-28
JP2022534261A5 true JP2022534261A5 (cg-RX-API-DMAC7.html) 2023-06-05
JP7696834B2 JP7696834B2 (ja) 2025-06-23

Family

ID=73551904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021570368A Active JP7696834B2 (ja) 2019-05-27 2020-05-26 Dna依存性タンパク質キナーゼ阻害剤

Country Status (12)

Country Link
US (1) US12630565B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976624A4 (cg-RX-API-DMAC7.html)
JP (1) JP7696834B2 (cg-RX-API-DMAC7.html)
KR (1) KR102961371B1 (cg-RX-API-DMAC7.html)
CN (1) CN113924305A (cg-RX-API-DMAC7.html)
AR (1) AR119018A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020281332B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021023824A8 (cg-RX-API-DMAC7.html)
CA (1) CA3137598A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021014455A (cg-RX-API-DMAC7.html)
TW (1) TWI899080B (cg-RX-API-DMAC7.html)
WO (1) WO2020238900A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021213460A1 (zh) * 2020-04-23 2021-10-28 山东轩竹医药科技有限公司 三并环类激酶抑制剂
CN114634521A (zh) * 2020-12-15 2022-06-17 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
TW202241901A (zh) * 2020-12-21 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮衍生物、其製備方法及其在醫藥上的應用
CN114656486B (zh) * 2020-12-22 2023-09-19 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
WO2022148354A1 (zh) * 2021-01-05 2022-07-14 山东轩竹医药科技有限公司 多环类激酶抑制剂
WO2022177302A1 (ko) * 2021-02-17 2022-08-25 보령제약 주식회사 Dna-pk 억제 활성을 갖는 피리미딘-융합 고리 화합물 및 이의 용도
CN116023394B (zh) * 2021-10-25 2025-08-12 山东轩竹医药科技有限公司 三环类激酶抑制剂的晶型
CN116023393B (zh) * 2021-10-25 2025-08-12 山东轩竹医药科技有限公司 三环类激酶抑制剂的晶型
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ck12抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CA3245866A1 (en) * 2022-03-14 2023-09-21 Huyabio International, Llc Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof
CN117003754B (zh) * 2022-04-28 2025-07-25 腾讯科技(深圳)有限公司 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
CN115322209B (zh) * 2022-07-19 2023-06-20 湖北理工学院 作为dna-pk抑制剂的三并环化合物
CN116239610B (zh) * 2023-02-23 2024-01-16 遵义医科大学珠海校区 一种嘧啶衍生物及其制备方法与在制备抗肿瘤药物中的应用
EP4720069A4 (en) * 2023-07-21 2026-07-22 Wei Zhong Substituted 2-AMINO-9-(3,3-DIFLOOROPIPERIDIN-4-YL)-7,9-DIHYDRO-8H-PURIN-8-ONE COMPOUNDS AND THEIR USE IN CANCER TREATMENT
WO2025179188A1 (en) * 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
JP5190271B2 (ja) * 2005-01-14 2013-04-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としての5員の環付加複素環式ピリミジン
ES2345997T3 (es) * 2005-01-14 2010-10-07 Janssen Pharmaceutica Nv Pirazolopiramidinas como inhibidores de las quinasas del ciclo celular.
KR20070104936A (ko) 2005-02-16 2007-10-29 아스트라제네카 아베 화합물
JP2006241089A (ja) * 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
EA022120B1 (ru) 2009-10-20 2015-11-30 Целльзом Лимитид Аналоги гетероциклил пиразолопиримидина в качестве ингибиторов jak
WO2011106168A1 (en) * 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
US20130035336A1 (en) * 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
WO2011134831A1 (en) 2010-04-30 2011-11-03 Cellzome Limited Pyrazole compounds as jak inhibitors
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
JP2013534233A (ja) * 2010-08-20 2013-09-02 セルゾーム リミティッド 選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
KR20140063700A (ko) 2011-09-20 2014-05-27 셀좀 리미티드 키나제 억제제로서의 피라졸로[4,3-c]피리딘 유도체
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
RS62649B1 (sr) * 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
WO2015115673A1 (en) * 2014-01-31 2015-08-06 Ono Pharmaceutical Co., Ltd. Fused imidazole compounds
DK3558997T3 (da) * 2016-12-20 2021-04-19 Astrazeneca Ab Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
JP7230053B2 (ja) 2017-12-05 2023-02-28 オスコテック インコーポレイテッド Lrrk2阻害剤としてのピロロ(ピラゾロ)ピリミジン誘導体
TWI820146B (zh) 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
CN110885331B (zh) 2018-09-11 2021-07-09 中国药科大学 一种6-氨基-1H-吡唑并[3,4-d]嘧啶类JAK激酶抑制剂的制备与应用

Similar Documents

Publication Publication Date Title
US11485710B2 (en) Heterocyclic amides as kinase inhibitors
US10695328B2 (en) Aryl dihydropyridinones and piperidinone MGAT2 inhibitors
US9394282B2 (en) Pyrazole carboxamides as Janus kinase inhibitors
EP2842955B1 (en) Trk-inhibiting compound
RU2013106755A (ru) 1,4,5,6-тетрагидропиримидин-2-иламины
JP2022546029A5 (cg-RX-API-DMAC7.html)
WO2010058846A1 (ja) 4,6-ジアミノニコチンアミド化合物
JPWO2012165399A1 (ja) イミダゾピリジン化合物
HRP20230388T1 (hr) Inhibitori oksazin monoacilglicerol lipaze (magl)
JP2022543666A5 (cg-RX-API-DMAC7.html)
JP2008528477A (ja) 化合物
HRP20250833T1 (hr) Derivati alfa-d-galaktopiranozida supstituirani triazolil metilom
JP2013542267A5 (cg-RX-API-DMAC7.html)
JP2023545046A5 (cg-RX-API-DMAC7.html)
CN118076354A (zh) 用mnk抑制剂治疗偏头痛的方法
JP2022510700A5 (cg-RX-API-DMAC7.html)
JP2025505609A5 (cg-RX-API-DMAC7.html)
RU2382784C2 (ru) Новые пиперидинзамещенные диаминотиазолы
JP2023550840A5 (cg-RX-API-DMAC7.html)
RU2021136517A (ru) Ингибитор ДНК-зависимой протеинкиназы
TW202136237A (zh) RORγt抑制劑及其製備方法和用途
TW202606685A (zh) 含有環烷基和哌啶基的二胺基亞甲基嘧啶-2,4,6-三酮的副甲狀腺素1受體和腸促胰島素受體的激動劑
US20220009891A1 (en) (r) enanatiomer of aplexone
RU2025102588A (ru) Фармацевтические композиции, содержащие ингибиторы геликазы wrn
HK1245244B (en) Heterocyclic amides as kinase inhibitors